Abstract
To evaluate the accuracy of 68Gallium prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) vs. CT combined with bone scan in the clinical staging of high-risk prostate cancer (PCa). From January 2020 to October 2021, 30 patients underwent clinical staging according to 68Ga-PSMA PET/TC, lung-abdominal CT and Technetium-99m bone scan. 68Ga-PSMA PET/CT demonstrated a better accuracy in comparison with CT plus bone scan in the diagnosis of node metastases at definitive histology (76.9% vs. 46.1%; p=0.001). The 68Ga-PSMA PET/CT was more accurate than CT and bone scan in the staging of high-risk PCa, leading to a change in the therapeutic strategy in 10% of the cases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
